In reaction to acquisition buzz in the market’s grapevine, Maxim’s Jason McCarthy is out boosting his price target on Juno stock.
Juno Therapeutics Inc (NASDAQ:JUNO) shares gained 9% after the company said it will present updated clinical and preclinical results from the company and …
